HomeCompareRMHB vs JNJ

RMHB vs JNJ: Dividend Comparison 2026

RMHB yields 90909.09% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RMHB wins by $1.8657767678438335e+26M in total portfolio value
10 years
RMHB
RMHB
● Live price
90909.09%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8657767678438335e+26M
Annual income
$186,174,819,330,989,220,000,000,000,000,000.00
Full RMHB calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — RMHB vs JNJ

📍 RMHB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRMHBJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RMHB + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RMHB pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RMHB
Annual income on $10K today (after 15% tax)
$7,727,272.73/yr
After 10yr DRIP, annual income (after tax)
$158,248,596,431,340,840,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, RMHB beats the other by $158,248,596,431,340,840,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RMHB + JNJ for your $10,000?

RMHB: 50%JNJ: 50%
100% JNJ50/50100% RMHB
Portfolio after 10yr
$9.328883839219167e+25M
Annual income
$93,087,409,665,494,610,000,000,000,000,000.00/yr
Blended yield
99.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RMHB
No analyst data
Altman Z
-25.2
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RMHB buys
0
JNJ buys
0
No recent congressional trades found for RMHB or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRMHBJNJ
Forward yield90909.09%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1.8657767678438335e+26M$30.3K
Annual income after 10y$186,174,819,330,989,220,000,000,000,000,000.00$4,689.40
Total dividends collected$1.865512718252454e+26M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RMHB vs JNJ ($10,000, DRIP)

YearRMHB PortfolioRMHB Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$9,101,609$9,090,909.09$10,592$272.30+$9.09MRMHB
2$7,742,626,649$7,732,887,927.71$11,289$357.73+$7742.62MRMHB
3$6,156,202,768,855$6,147,918,158,340.57$12,123$472.89+$6156202.76MRMHB
4$4,575,037,364,168,400$4,568,450,227,205,725.00$13,141$629.86+$4575037364.16MRMHB
5$3,177,871,744,582,025,000$3,172,976,454,602,365,000.00$14,408$846.81+$3177871744582.01MRMHB
6$2,063,199,081,001,827,700,000$2,059,798,758,235,125,000,000.00$16,021$1,151.60+$2063199081001827.75MRMHB
7$1,252,022,771,935,710,300,000,000$1,249,815,148,919,038,400,000,000.00$18,122$1,588.22+$1252022771935710208.00MRMHB
8$710,154,989,871,965,200,000,000,000$708,815,325,505,994,000,000,000,000.00$20,930$2,228.20+$710154989871965274112.00MRMHB
9$376,502,292,891,686,800,000,000,000,000$375,742,427,052,523,800,000,000,000,000.00$24,792$3,191.91+$3.7650229289168676e+23MRMHB
10$186,577,676,784,383,340,000,000,000,000,000$186,174,819,330,989,220,000,000,000,000,000.00$30,274$4,689.40+$1.8657767678438335e+26MRMHB

RMHB vs JNJ: Complete Analysis 2026

RMHBStock

Rocky Mountain High Brands, Inc. operates as a lifestyle brand management company. The company develops, manufactures, markets, and distributes hemp oil and hemp extract-infused products. It provides products in various categories, including beverage, food, fitness, skin care, and other products. The company offers CBD-infused waters, gummies, water soluble concentrates, tinctures, capsules, triple relief salves, and serenity hemp lotions; naturally flavored citrus and mango energy drinks, low calorie coconut energy lime, and naturally flavored lemonade and black tea; and hemp-infused mango and mixed berry energy shots, as well as high alkaline spring water. It provides its products under the Rocky Mountain High, HEMPd, HEMPFIT, Smarterita, Totally Hemp Crazy, Blue Leaf, Rock the Road Trip, Eagle Spirit, and Eagle Paa names, as well as various private labels. The company markets its products through distributors, retailers, and consumers, as well as online. The company was formerly known as Totally Hemp Crazy Inc. and changed its name to Rocky Mountain High Brands, Inc. in October 2014. Rocky Mountain High Brands, Inc. is based in Plano, Texas.

Full RMHB Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this RMHB vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RMHB vs SCHDRMHB vs JEPIRMHB vs ORMHB vs KORMHB vs MAINRMHB vs ABBVRMHB vs MRKRMHB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.